Browsing by Author "Uzunca K."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP
    (2012) Bodur H.; Ataman Ş.; BuǧdaycI D.S.; Rezvani A.; Nas K.; Uzunca K.; EmlakçIoǧlu E.; Karatepe A.G.; Durmuş B.; Sezgin M.; Ayhan F.; Yazgan P.; Duruöz T.; Yener M.; Gürgan A.; KIrnap M.; Çakar E.; Altan L.; Soydemir R.; ÇapkIn E.; Tekeoǧlu I.; AydIn G.; Günendi Z.; NacIr B.; SallI A.; Öztürk C.; Memiş A.; Turan Y.; Kozanoǧlu E.; Sivrioǧlu K.
    A web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 ± 10.7 years). Mean disease duration was 12.1 ± 8.5 years, and mean time from initial symptom to diagnosis was 5 ± 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was ≥4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses. © 2010 Springer-Verlag.
  • No Thumbnail Available
    Item
    Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
    (2013) Duruöz M.T.; Doward L.; Turan Y.; Cerrahoglu L.; Yurtkuran M.; Calis M.; Tas N.; Ozgocmen S.; Yoleri O.; Durmaz B.; Oncel S.; Tuncer T.; Sendur O.; Birtane M.; Tuzun F.; Bingol U.; Kirnap M.; Celik Erturk G.; Ardicoglu O.; Memis A.; Atamaz F.; Kizil R.; Kacar C.; Gurer G.; Uzunca K.; Sari H.
    The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is a disease-specific measure of needs-based quality of life developed in the UK and the Netherlands. This study describes translation, validation, and reliability of the scale into Turkish population. The ASQoL was translated into Turkish using the dual-panel process. Content validity was assessed via cognitive debriefing interviews with ankylosing spondylitis (AS) patients. Patients with AS according to modified New York criteria were recruited into the study from 12 hospitals of all part of Turkey. Psychometric and scaling properties were assessed via a two administration survey involving the ASQoL, the Nottingham Health Profile (NHP), Bath AS Functional Index (BASFI), and Bath AS Disease Activity Index (BASDAI). Classical psychometrics assessed reliability, convergent validity (correlation of ASQoL with NHP, BASFI, and BASDAI) and discriminative validity (correlation of ASQoL with perceived AS-severity and general health). Cognitive debriefing showed the new Turkish ASQoL to be clear, relevant, and comprehensive. Completed survey questionnaires were received from 277 AS patients (80 % Male, mean age 42.2/SD 11.6, mean AS duration 9.4 years/SD 9.4). Test-retest reliability was excellent (0.96), indicating low random measurement error for the scale. Correlations of ASQoL with NHP sections were low to moderate (NHP Sleep 0.34; NHP Emotional Reactions 0.83) suggesting the measures assess related but distinct constructs. The measure was able to discriminate between patients based on their perceived disease severity (p < 0.0001) and self-reported general health (p < 0.0001). The Turkish version of ASQoL has good reliability and validity properties. It is practical and useful scale to assess the quality of life in AS patients in Turkish population. © 2013 Springer-Verlag Berlin Heidelberg.
  • No Thumbnail Available
    Item
    Prevalence of rheumatoid arthritis and spondyloarthritis in Turkey: A nationwide study
    (Turkish League Against Rheumatism (TLAR), 2018) Tuncer T.; Gilgil E.; Kaçar C.; Kurtaiş Y.; Kutlay Ş.; Bütün B.; Yalçin P.; Akarirmak Ü.; Altan L.; Ardiç F.; Ardiçoğlu Ö.; Altay Z.; Cantürk F.; Cerrahoğlu L.; Çevik R.; Demir H.; Durmaz B.; Dursun N.; Duruöz T.; Erdoğan C.; Evcik D.; Gürsoy S.; Hizmetli S.; Kaptanoğlu E.; Kayhan Ö.; Kirnap M.; Kokino S.; Kozanoğlu E.; Kuran B.; Nas K.; Öncel S.; Sindel D.; Orkun S.; Sarpel T.; Savaş S.; Şendur Ö.F.; Şenel K.; Uğurlu H.; Uzunca K.; Tekeoğlu İ.; Guillemin F.
    Objectives: This study aims to estimate the prevalence of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in Turkey using the same telephone questionnaire developed for screening RA and SpA in France and used in Serbia and Lithuania. Material and methods: The study was performed in two steps. In step I, the French questionnaire was translated into Turkish and validated through a group of 200 patients (80 males, 120 females; mean age 44.0±13.1 years; range, 19 to 75 years) followed up at the rheumatology departments of University Hospitals in Antalya and Ankara. In step II, the validated Turkish questionnaire was administered face-to-face to randomly selected 4,012 subjects (1,670 males, 2,342 females; mean age 41.5±16.8 years; range, 16 to 97 years) by trained general practitioners across the country, in 25 provinces for case detection. The subjects who were suspected of having RA or SpA in accordance with the questionnaire were invited to the nearest university hospital for rheumatologic examination in order to confirm the diagnosis. Results: In step II, a total of 25 subjects (2 males, 23 females) were diagnosed as RA. The standardized RA prevalence for the general population of Turkey was calculated as 0.56% (95% confidence interval [CI]; 0.33-0.79), 0.10% (95% CI;-0.05-0.25) for males and 0.89% (95% CI; 0.51-1.27) for females. A total of 18 subjects (3 males, 15 females) were diagnosed as SpA. The standardized SpA prevalence for the general population of Turkey was 0.46% (95% CI; 0.25-0.67), 0.17% (95% CI;-0.03-0.37) for males and 0.65% (95% CI; 0.32-0.98) for females. The prevalence of RA was highest in the Northern region (2.00%) and the prevalence of SpA was highest in the Central region (1.49%). Conclusion: The prevalences of RA and SpA in Turkey are close to each other and there are significant inter-regional variations in prevalences of both RA and SpA. © 2018 Turkish League Against Rheumatism. All rights reserved.